Pine Valley Investments Ltd Liability Co Buys Shares of 48,469 Novo Nordisk A/S $NVO

Pine Valley Investments Ltd Liability Co bought a new position in Novo Nordisk A/S (NYSE:NVO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 48,469 shares of the company’s stock, valued at approximately $2,324,000.

Other hedge funds have also modified their holdings of the company. Capital Investment Counsel LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $3,727,000. Marathon Capital Management increased its position in shares of Novo Nordisk A/S by 43.9% during the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after purchasing an additional 25,230 shares in the last quarter. Burkett Asset Management Ltd acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth $1,823,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novo Nordisk A/S by 2,414.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after purchasing an additional 286,034 shares during the last quarter. Finally, Myriad Asset Management Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $1,846,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Wall Street Analysts Forecast Growth

NVO has been the topic of several research analyst reports. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Four equities research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $45.91 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock’s fifty day moving average price is $47.36 and its 200 day moving average price is $44.51. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market cap of $204.99 billion, a price-to-earnings ratio of 11.23, a PEG ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 42.79%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.